Clinical Trials Logo

Hypertension clinical trials

View clinical trials related to Hypertension.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT03716960 Completed - Hypertension Clinical Trials

The Effects of Pumpkin Seed Oil Supplementation on Cardiovascular Function in Postmenopausal Women.

Start date: September 1, 2017
Phase: N/A
Study type: Interventional

Postmenopausal women have a higher prevalence of cardiovascular (CV) disease than age-match men. Growing evidence from rat studies have demonstrated CV-protective effects of pumpkin seed oil (PSO). The investigators hypothesis is that PSO would improve CV health in postmenopausal women.

NCT ID: NCT03693638 Completed - Clinical trials for Pregnancy Induced Hypertension

Fractionated Vs Single Dose Injection for Spinal C-Section in Patients With Pregnancy-Induced Hypertension

Start date: January 1, 2018
Phase: N/A
Study type: Interventional

The aim of this study was to compare haemodynamic changes, total dose of ephedrin requirement, and level of sensory blockade between fractionated dose and single dose spinal anesthesia injection in obstetric patients with pregnancy-induced hypertension who underwent Caesarean section

NCT ID: NCT03688698 Completed - Clinical trials for Pulmonary Arterial Hypertension

PET/MRI in PAH Patients

Start date: May 1, 2016
Phase:
Study type: Observational [Patient Registry]

Aim of the study is to compare novel parameters of right ventricle (RV) function from right heart catheterization (RHC) and magnetic resonance imaging (MRI) with PET-derived RV FDG uptake.

NCT ID: NCT03680313 Completed - Hypertension Clinical Trials

Cardio-ankle Vascular Index (CAVI) in Hypertension Patients After One Year of Treatment

Start date: May 1, 2016
Phase:
Study type: Observational

This study aimed to evaluate the role of the cardio-ankle vascular index (CAVI) in evaluating arterial stiffness changes, the degree of atherosclerosis in patients with hypertension after 1 year of treatment and analysis the correlation between CAVI and cardiovascular risk factors.

NCT ID: NCT03674918 Completed - Clinical trials for Arterial Hypertension

Reliable Hypertension Diagnosis Based on 24 ABPM

Start date: July 1, 2015
Phase:
Study type: Observational

24 h blood pressure monitoring can help to define which is the optimal timing and frequency of measurements

NCT ID: NCT03667794 Completed - Clinical trials for Pulmonary Hypertension

Evaluation of Novel Lung Function Parameters in Patients With Pulmonary Hypertension (PH)

Start date: July 1, 2015
Phase:
Study type: Observational

Little is known about affection of small airways in patients with pulmonary hypertension as well as the ideal diagnostic approach. The investigators therefore aimed to evaluate novel or not widely used lung function tests for the evaluation of airway function in patients with PH.

NCT ID: NCT03660618 Completed - Hypertension Clinical Trials

LSFG-SKIN, Laser Speckle Flowgraphy

Start date: May 23, 2017
Phase: N/A
Study type: Interventional

The purpose of this project is to quantify normal and abnormal skin blood flow regionally in different areas of the body(face, extremities, over burns and wounds) at baseline and over time in response to treatment or environmental changes, such as temperature, light and pressure.

NCT ID: NCT03659149 Completed - Hypertension Clinical Trials

Pharmacokinetics and Safety Profile of CKD-333

Start date: August 8, 2018
Phase: Phase 1
Study type: Interventional

Compare the pharmacokinetic characteristics and safety between CKD-333 tablet and CKD-330, D086 combination

NCT ID: NCT03657472 Completed - Hypertension Clinical Trials

Bioequivalence Study of CJ-30061 in Healthy Male Volunteers

Start date: September 19, 2016
Phase: Phase 1
Study type: Interventional

To compare the pharmacokinetics and safety after a single dose administration of CJ-30061 and co-administration of Exforge® 5/160mg, Lipitor® 20mg in healthy adult volunteers

NCT ID: NCT03649828 Completed - Hypertension Clinical Trials

Kefir and Metabolic Syndrome

Start date: July 1, 2016
Phase: N/A
Study type: Interventional

Metabolic Syndrome (MS) contributes to the development of cardiovascular diseases (CVD). According to the World Health Organization (WHO), CVDs are the leading causes of death in the world. According to epidemiological data from the Ministry of Health, these diseases account for 29.4% of all deaths recorded in Brazil annually. Kefir is obtained by fermenting milk with kefir grains and has been recommended as a therapeutic form for the treatment of various clinical conditions. The hypothesis of the present study is that the daily intake of fermented beverages with kefir grains may reduce the risk factors associated with MS, thus reducing the incidence of CVD. A clinical trial was conducted with 48 volunteers, who presented at least three criteria for the diagnosis of MS. The subjects were divided into two groups that received for eleven weeks fermented dairy drink with kefir (KG) grains or homemade curd (CG). Weight and height measurements were taken to calculate BMI. The body composition evaluation was performed by determining the percentage of body fat and waist circumference (WC). The measurements of systolic blood pressure (SBP) and diastolic blood pressure (DBP) were taken. Blood samples were analyzed for fasting glycemia, glycated hemoglobin (HA1c), total cholesterol (TC), HDL cholesterol, triglycerides (Tg), C-reactive protein (CRP), aspartate aminotransferase (AST), Alanine Aminotransferase (ALT), Creatinophosphokinase (CPK), γ-Glutamyl Transferase (γ-GT), Urea Nitrogen, Urea and Creatinine. The level of non-HDL cholesterol (n-HDL) was determined by calculation. The Framingham score was used to assess the risk of developing cardiovascular events over the next ten years. Eleven weeks into the experiment, all measurements of body evaluation, SBP and DBP and biochemical analysis of blood were reevaluated.